CO5130020A1 - Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide - Google Patents

Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide

Info

Publication number
CO5130020A1
CO5130020A1 CO99052525A CO99052525A CO5130020A1 CO 5130020 A1 CO5130020 A1 CO 5130020A1 CO 99052525 A CO99052525 A CO 99052525A CO 99052525 A CO99052525 A CO 99052525A CO 5130020 A1 CO5130020 A1 CO 5130020A1
Authority
CO
Colombia
Prior art keywords
hardness
increasing
tenacity
manufacture
product containing
Prior art date
Application number
CO99052525A
Other languages
English (en)
Spanish (es)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5130020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5130020A1 publication Critical patent/CO5130020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
CO99052525A 1998-08-19 1999-08-19 Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide CO5130020A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
CO5130020A1 true CO5130020A1 (es) 2002-02-27

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99052525A CO5130020A1 (es) 1998-08-19 1999-08-19 Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP2266598B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1769804T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2393200T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU230697B1 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT2907522T (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
MXPA04006728A (es) * 2002-01-10 2005-08-19 Osteotrophin Llc Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos.
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2539357A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CN101217972B (zh) * 2005-05-11 2013-05-29 尤尼基因实验室公司 促进骨形成和保持的方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2537539B1 (en) 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymeric Tissue Sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
KR20190095552A (ko) 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
ES2833277T3 (es) 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017136195A1 (en) 2016-02-01 2017-08-10 Eli Lilly And Company Parathyroid hormone – anti-rankl antibody fusion compounds
CN110520148A (zh) * 2017-02-01 2019-11-29 约翰霍普金斯大学 甲状旁腺激素与退行性椎间盘疾病的再生
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
CA2205959A1 (en) * 1994-12-19 1996-06-27 Michael Chorev Continuous low-dose administration of parathyroid hormone or its agonist
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
SK76797A3 (en) * 1994-12-22 1998-02-04 Astra Ab Therapeutic preparation for inhalation containing parathyroid hormone, pth
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
TR200000649T2 (tr) * 1997-09-09 2000-09-21 F.Hoffmann-La Roche Ag PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
CY1113343T1 (el) 2016-06-22
ATE231000T1 (de) 2003-02-15
NO20005947D0 (no) 2000-11-24
ES2393200T3 (es) 2012-12-19
ES2621653T3 (es) 2017-07-04
HUP0101594A2 (hu) 2001-11-28
DK2266598T3 (en) 2017-05-15
US6977077B1 (en) 2005-12-20
CN1308545A (zh) 2001-08-15
JP2017190332A (ja) 2017-10-19
DK2907522T1 (da) 2015-10-19
IL138829A0 (en) 2001-10-31
ES2549551T1 (es) 2015-10-29
IL138829A (en) 2011-01-31
PT1769804E (pt) 2012-11-13
ES2190244T3 (es) 2003-07-16
NO323984B1 (no) 2007-07-30
KR20010072763A (ko) 2001-07-31
ID29039A (id) 2001-07-26
PL201688B1 (pl) 2009-04-30
TW576747B (en) 2004-02-21
EP2266598A1 (en) 2010-12-29
CN1205997C (zh) 2005-06-15
NZ507056A (en) 2003-10-31
HU230697B1 (hu) 2017-09-28
EP1059933A1 (en) 2000-12-20
AU746277B2 (en) 2002-04-18
DK2907522T3 (en) 2017-10-23
EP1059933B1 (en) 2003-01-15
NO20072983L (no) 2000-11-24
PT1059933E (pt) 2003-06-30
CY1119552T1 (el) 2018-03-07
BR9909445A (pt) 2000-12-12
EA003362B1 (ru) 2003-04-24
HK1030545A1 (en) 2001-05-11
HK1212602A1 (en) 2016-06-17
JP2015028065A (ja) 2015-02-12
EP2907522A1 (en) 2015-08-19
ES2549551T3 (es) 2017-11-27
TR200003455T2 (tr) 2001-06-21
AR033639A1 (es) 2004-01-07
PE20001089A1 (es) 2000-11-04
DE15152726T1 (de) 2015-12-10
PT2266598T (pt) 2017-05-02
JP2014139220A (ja) 2014-07-31
HU1200430D0 (hu) 2001-11-28
PL343595A1 (en) 2001-08-27
DE69904918T2 (de) 2003-11-13
CA2325371A1 (en) 2000-03-02
AU5575099A (en) 2000-03-14
WO2000010596A1 (en) 2000-03-02
HUP0101594A3 (en) 2002-01-28
CZ20004134A3 (cs) 2001-08-15
US20050197294A1 (en) 2005-09-08
JP2002523375A (ja) 2002-07-30
UA72205C2 (uk) 2005-02-15
PT2907522T (pt) 2017-10-23
JP2011021035A (ja) 2011-02-03
DK1059933T3 (da) 2003-04-07
CZ301017B6 (cs) 2009-10-14
DK1769804T3 (da) 2012-10-15
NO20005947L (no) 2000-11-24
MY129227A (en) 2007-03-30
HK1102496A1 (en) 2007-11-23
HRP20000755A2 (en) 2001-02-28
DZ2873A1 (fr) 2003-12-15
JP6177718B2 (ja) 2017-08-09
EP2266598B1 (en) 2017-02-22
EP2907522B1 (en) 2017-08-02
KR100454207B1 (ko) 2004-10-26
US7163684B2 (en) 2007-01-16
CA2325371C (en) 2004-08-17
EA200001015A1 (ru) 2001-02-26
DE69904918D1 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
CO5130020A1 (es) Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
EP0830138A4 (en) USE OF FIBROBLAST GROWTH FACTORS FOR STIMULATING BONE GROWTH
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
ATE319812T1 (de) Knochen-vorläufer-zellen: zusammensetzungen und methoden
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
GB0001309D0 (en) Valve arrangement
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
MXPA04005583A (es) Composicion para la promocion del crecimiento oseo y mantenimiento de la salud osea.
GB0109146D0 (en) Treatment of type 2 diabetes
CY2495B1 (en) Sulfonamides.
SE9404196D0 (sv) New antithrombotic formulation
EP1072273A4 (en) VASKULARISIERUNGSINHIBITOREN
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
SE9603725D0 (sv) New teatment
DE69821929D1 (de) Pharmazeutische zusammensetzung zur behandlung von parkinsonkrankheit oder depression
BG105275A (en) Tan-1057 derivatives
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
NZ326345A (en) Composition containing diosgenin
ZA943171B (en) Thrombin-inhibitors.
CR20230472A (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE157255T1 (de) Zusammensetzung zur bekämpfung von dermatomykosen und deren erregern sowie von schweissbildung und körpergeruch
DE69930624D1 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie